본문으로 건너뛰기
AI NEWS JOURNAL
arXiv cs.LGAI NEWS / JOURNAL

ReMedI: 제어 가능한 분자 최적화를 위한 추론 시 정제 및 자기 디스틸레이션

arXiv:2610.32103v1 발표 유형: 신규 초록: 약물 개발에서 리드 최적화는 투과성을 높이고 독성을 낮추는 등 상충되는 특성을 개선하는 동시에, 리드의 효능을 저해할 수 있는 골격 변경을 최소화해야 한다. C-MORAL과 같은 RL 기반 사후 학습 방법은 분자 언어 모델을 미세 조정하여 관심 있는 목표를 위해 분자 리드를 직접 최적화함으로써 이러한 문제를 해결하려 하지만, 이는 비용이 많이 드는 특정 작업용 데이터셋에 의존하며 다목적 최적화(MOO) 달성에도 어려움을 겪는다. 우리는 사전 훈련된 모델이 이미 제로샷 생성으로는 효율적으로 도달하기 어려운 유용한 분자 수정 정보를 포함하고 있을 수 있다고 주장한다. 제로샷 생성의 제한된 탐색 능력에 착안하여, 우리는 효율적인 메트로폴리스-헤스팅스 탐색 전략을 개발하여 베팅…

번역 대기 중입니다. 완료되면 자동 업데이트됩니다.

Abstract:In drug development, lead optimization must improve competing properties, such as increasing permeability and reducing toxicity, while limiting scaffold changes that could compromise the lead's potency. RL-based post-training, such as C-MORAL, addresses this problem by fine-tuning molecular language models to directly optimize molecular leads for objectives of interest, which relies on expensive task-specific datasets and faces challenges in achieving multi-objective optimization (MOO). We argue a pre-trained model may already contain useful molecular edits that zero-shot generation cannot efficiently reach. Motivated by the limited search capabilities of zero-shot generation, we develop an efficient Metropolis-Hastings search strategy to better explore the proposal distribution. We propose ReMedI, which uses the molecular language model as a base proposer for inference-time alignment. Given a lead and a set of multi-objective tasks, the model proposes edits conditioned on the current molecule, while Metropolis--Hastings refinement guides sequential edits under an objective for property improvement, preservation, and lead similarity. On both C-MuMOInstruct and SMDD benchmarks, refinement improves frozen base models across three backbones, reaching significantly higher multi-objective optimization success rates compared to baselines. These search traces can then distilled into the base model which improves zero-shot generation and subsequent search using approximately 7.8 times less training molecular leads than that of C-MORAL. ReMedI achieves approximately 2.8 times the strict-success coverage of RL baseline C-MORAL, including on out-of-distribution tasks, with matched lead-relative similarity.

Submission history

Access Paper:

View PDF

HTML (experimental)

TeX Source

Additional Features

Audio Summary

Current browse context:

References & Citations

Google Scholar

Semantic Scholar

Bookmark

Institution

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

자료 출처

arXiv cs.LG
← 전체 소식 이어 읽기